Interviews

Jyoti Srivastava, PhD, discusses a study investigating methods to boost inhibitor function in advanced melanoma.

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in melanoma.

David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, potentially guiding future therapy decisions.

Ahmad Abuhelwa, MD, discusses the significance of a study exploring statin use in patients with chronic lymphocytic leukemia.

A transformative milestone in cancer care has arrived in Central New Jersey with the reopening of the John Theurer Cancer Center at 80 James Street in Edison.

Sofia Chernoff, PsyD, MSEd, discussed how cognitive behavioral therapy helps cancer patients manage emotional challenges by modifying negative thoughts and behaviors.

Ahmad Abuhelwa, MD, discusses an analysis exploring the connection between statins and better outcomes in patients with CLL and SLL.

Ahmad Abuhelwa, MD, discusses the mechanisms of statins and how they can play a surprisingly beneficial role in patients with chronic lymphocytic leukemia.

Ahmad Tarhini, MD, PhD, provides data into his research looking at inherited genetic variations and genetic ancestry in patients with high-risk melanoma.

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ciloleucel in large B-cell lymphoma.

Felix Guerrero-Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of nivolumab plus ipilimumab and look back on last year's ODAC meeting on its use in PD-L1–negative gastrointestinal cancers.

Ahmad Tarhini, MD, PhD, discusses inherited genetic variations and genetic ancestry, particularly for patients with high-risk melanoma.

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Mark D. Tyson, MD, MPH, discusses cretostimogene and how it varies from other therapies for bladder cancer.

Mark Tyson, MD, MPH, discusses practice-changing data from the phase 3 BOND-003 study.

In an interview, Stacy Loeb, MD, discussed a study analyzing prostate cancer misinformation on social media.

Jethro C.C. Kwong discusses a novel artificial intelligence-based model, PROGRxN-BCa.

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic hormone-sensitive prostate cancer.

Sophia Kamran, MD, discusses how salvage therapy after biochemical recurrence may improve outcomes for patients with prostate cancer.

Felix Guerrero-Ramos, MD, PhD, discusses findings from cohort 4 of the phase 2 SunRISe-1 trial of TAR-200 in patients with high-risk, BCG-unresponsive NMIBC with papillary-only disease.

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

Joseph Jacob, MD, discusses data from the phase 2b SunRISe-1 study, cohort 2, evaluating TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.

Colin P.N. Dinney, MD, discusses updated translational analyses from the BOND-003 and CORE-001 trials.

Arvind Trindade, MD, discusses a large database study looking at rising rates of pancreatic and colon cancer in young adults.